Natus Medical Announces Second Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Natus Medical Announces Second Quarter 2014 Financial Results
  • Reports organic revenue growth of 5% for the quarter
  • Reports record non-GAAP EPS of $0.28
  • Increases annual revenue and non-GAAP earnings guidance

SAN CARLOS, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (Nasdaq: BABY ) today announced financial results for the three months ended June 30, 2014.

For the second quarter ended June 30, 2014, the Company reported revenue of $86.3 million, an increase of 5% compared to $82.3 million reported for the second quarter of 2013. Net income was $7.7 million, or $0.24 per diluted share, compared with net income of $4.0 million, or $0.13 per diluted share in the second quarter of 2013.

The Company reported record second quarter non-GAAP earnings of $0.28 per diluted share, up 33% compared to $0.21 per diluted share reported for the second quarter of 2013.

The Company reduced total debt by $16.5 million and repurchased $1.2 million of company stock during the second quarter. Cash and cash equivalents decreased by $3.6 million to $56.0 million during the quarter.

"I am very pleased with our second quarter results as our record revenues and earnings exceeded our guidance. I am most satisfied with our 5% organic revenue growth in the quarter as reestablishing consistent organic revenue growth is a goal for Natus in 2014. Our non-GAAP operating margin increased to 13% up from 11% last year in the quarter. We continue to make progress toward our long term full year non-GAAP operating margin goal of 20%."

"Both Neurology and Newborn Care again performed well in all geographies. Our recently launched Hearing Screening Service grew rapidly during the quarter and we ended the quarter with 22 hospitals under contract. We continue to be very excited about this opportunity."

Financial Guidance

The Company provided revenue and earnings guidance for the third quarter and increased its non-GAAP EPS guidance for the full year 2014.

For the third quarter of 2014, the Company expects revenue of $86 million to $89 million and non-GAAP earnings per share of $0.28 to $0.32.

The Company updated its non-GAAP earnings guidance for the full year 2014 and now expects to report non-GAAP earnings per share of $1.20 to $1.23, an increase from previous guidance of $1.18 to $1.21. Full year 2014 revenue was increased to $347.5 million to $352.5 million compared to previous guidance of $345.0 million to $350.0 million.

The Company's non-GAAP earnings guidance excludes amortization of acquisition related intangibles, acquisition related charges, restructuring charges, and their related tax effects. Non-GAAP earnings guidance includes the impact of expensing employee share based compensation. All non-GAAP earnings per share amounts are on a diluted basis.

Use of Non-GAAP Financial Measures

The Company's non-GAAP results exclude amortization expense associated with certain acquisition-related intangibles, restructuring charges, direct costs of acquisitions and the related tax effects. A reconciliation between non-GAAP and GAAP financial measures is included on page 6 of this press release.

The Company believes that the presentation of results excluding these charges provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results. Therefore, the Company believes these non-GAAP financial measures facilitate comparison of operating results across reporting periods.

The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.

Conference Call

Natus has scheduled an investment-community conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) today, July 23, 2014. Individuals interested in listening to the conference call may do so by dialing 1-866-515-2915 for domestic callers, or 1-617-399-5129 for international callers, and entering reservation code 23770449. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-888-286-8010 for domestic callers, or 1-617-801-6888 for international callers, and entering reservation code 43159437.

The conference call also will be available real-time via the Internet at http://investor.natus.com , and a recording of the call will be available on the Company's Web site for 90 days following the completion of the call.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.

Additional information about Natus Medical can be found at www.natus.com .

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding our long term goal of driving non-GAAP operating margins to 20%, revenue and non‑GAAP profitability in the third quarter and full year 2014. These statements relate to estimates and assumptions regarding future events including Natus' future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, risks associated with bringing new products to market and integrating acquired businesses, and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2013, and its quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts) 
 
  Quarter Ended  Year to Date 
  June 30,
2014
June 30,
2013
June 30,
2014
June 30,
2013
         
Revenue  $ 86,325  $ 82,250  $ 171,948  $ 168,084
Cost of revenue  35,295  33,859  71,028  70,460
Gross profit  51,030  48,391  100,920  97,624
Gross profit margin 59.1% 58.8% 58.7% 58.1%
Operating expenses:        
Marketing and selling  22,028  21,848  43,451  43,969
Research and development  7,873  8,626  15,380  16,801
General and administrative  10,823  11,759  23,103  25,837
Total operating expenses  40,724  42,233  81,934  86,607
Income from operations  10,306  6,158  18,986  11,017
Other income/(expense), net  795  (523)  1,107  (856)
Income before tax  11,101  5,635  20,093  10,161
Provision for income tax expense  3,359  1,615  6,101  2,699
Net income   $ 7,742  $ 4,020  $ 13,992  $ 7,462
Earnings per share:        
Basic  $ 0.25  $ 0.14  $ 0.45  $ 0.25
Diluted  $ 0.24  $ 0.13  $ 0.43  $ 0.24
         
Weighted-average shares:        
Basic  31,424  29,666  31,244  29,685
Diluted  32,444  30,468  32,315  30,470
         
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands) 
 
  June 30, June 30,
  2014 2013
ASSETS Q2-14 Q2-13
     
Current assets:    
Cash and cash equivalents   $ 56,018  $ 28,910
Accounts receivable, net  76,910  87,557
Inventories   35,503  38,906
Other Current Assets  21,429  14,606
Total current assets   189,860  169,979
     
Property and equipment, net   21,108  25,842
Goodwill and Intangible assets  198,939  200,544
Other assets   9,806  8,445
Total assets   $ 419,713  $ 404,810
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
     
Current liabilities:    
Accounts payable   $ 24,979  $ 25,811
Current debt  10,409  10,182
Accrued liabilities   23,428  24,007
Deferred revenue   11,410  11,951
Total current liabilities   70,226  71,951
     
Long-term liabilities:    
Long-term debt, net  6,000  40,381
Other long-term liabilities   13,075  13,120
Total liabilities   89,301  125,452
Total stockholders' equity   330,412  279,358
Total liabilities and stockholders' equity   $ 419,713  $ 404,810
     
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (UNAUDITED)
(in thousands, except per share amounts) 
 
   Quarter Ended   Year to Date 
  June 30,
2014
June 30,
2013
June 30,
2014
June 30,
2013
GAAP based results:        
         
Income before provision for income tax   $ 11,101  $ 5,635  $ 20,093  $ 10,161
         
Non-GAAP adjustments:        
         
Amortization of acquired intangibles:        
Cost of revenue  157  791  1,202  1,565
Marketing and selling  (32)  684  757  1,335
Research and development  679  313  1,023  626
         
Intangible Asset Impairment Charges (M&S)  --  --  --  --
Restructuring charges (G&A)  218  1,040  853  653
Direct costs of acquisitions (G&A)  144  436  339  1,203
Non-GAAP income before provision for income tax  12,266  8,899  24,267  15,543
         
Income tax expense, as adjusted  3,336  2,509  7,050  4,596
         
Non-GAAP net income   $ 8,930  $ 6,390  $ 17,217  $ 10,947
Non-GAAP earnings per share:        
Basic  $ 0.28  $ 0.22  $ 0.55  $ 0.37
Diluted  $ 0.28  $ 0.21  $ 0.53  $ 0.36
         
Weighted-average shares used to compute        
Basic non-GAAP earnings per share  31,424  29,666  31,244  29,685
Diluted non-GAAP earnings per share  32,444  30,468  32,315  30,470
         
GAAP Gross profit  51,030  48,391  100,920  97,624
Amortization of intangibles  157  791  1,202  1,565
Non-GAAP Gross Profit  51,187  49,182  102,122  99,189
Non-GAAP Gross Margin 59.3% 59.8% 59.4% 59.0%
         
GAAP Operating profit  10,306  6,158  18,986  11,017
Amortization of intangibles  804  1,788  2,982  3,526
Restructuring and other charges  362  1,476  1,192  1,856
Non-GAAP Operating profit  11,471  9,422  23,160  16,399
Non-GAAP Operating margin 13.3% 11.5% 13.5% 9.8%

COMPANY CONTACT: Natus Medical Incorporated Jonathan A. Kennedy Sr. Vice President and Chief Financial Officer (650) 802-0400

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Sandler Partners Unveils 2025 Superstar Trip Destination

Updated Category News Views 179

Sandler Partners Unveils 2025 Superstar Trip Destination Sandler Partners is thrilled to reveal the highly anticipated location for its 2025 Superstar Trip, a special reward designed to honor Partners who have excelled in achieving their growth objectives for the year. The trip will take place at the stunning Susurros del Corazón Resort, located along the picturesque...

Continue Reading
e.l.f. Beauty Stock Insights: Understanding Market Trends Today

Updated Category News Views 309

Market Sentiment Surrounding e.l.f. Beauty Investors with substantial capital are showing a cautious approach towards e.l.f. Beauty (NYSE: ELF). This sentiment isn't just noise in the market; it reflects deeper strategies that should be on the radar of traders and analysts alike. There has been significant insight gleaned from public options activity which suggests that...

Continue Reading
Empowering Teens Through Free AI Bootcamp by Mark Cuban

Updated Category News Views 216

Empowering Teens Through Innovative AI Bootcamp Time is of the essence for high school students eager to launch their careers in technology with the Mark Cuban Foundation's Artificial Intelligence (AI) Bootcamp. Hosted by Girls Inc., this remarkable initiative opens doors for teens interested in the cutting-edge realm of AI. Applications for participation are set to close...

Continue Reading
BlackRock's Major Acquisition of Global Infrastructure Partners

Updated Category News Views 275

BlackRock Secures $12.5 Billion Deal The U.S. Federal Energy Regulatory Commission has recently approved BlackRock's substantial acquisition of Global Infrastructure Partners, valued at $12.5 billion. This approval is a pivotal moment for BlackRock as it seeks to broaden its reach within the infrastructure investment sector. Details of the Acquisition In this significant...

Continue Reading
Key Analyst Initiations Impacting Major Stocks This Week

Updated Category News Views 120

Recent Analyst Initiations: An Overview In the dynamic realm of stock trading, the insights of analysts can have a major impact on market trends. Recently, Wall Street has made significant adjustments to their ratings for several well-known stocks. Below, we summarize the latest analyst actions that may affect investor decisions this week. Arm Holdings plc (NASDAQ: ARM)...

Continue Reading